These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36126186)

  • 1. Yttrium-90 transarterial radioembolization for liver metastases from medullary thyroid cancer.
    Puleo L; Agate L; Bargellini I; Boni G; Piaggi P; Traino C; Depalo T; Lorenzoni G; Bianchi F; Volterrani D; Brogioni S; Bottici V; Brunetto MR; Coco B; Molinaro E; Elisei R
    Eur Thyroid J; 2022 Dec; 11(6):. PubMed ID: 36126186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of treatment response to transarterial radioembolization of liver metastases: Radiomics analysis of pre-treatment cone-beam CT: A proof of concept study.
    Kobe A; Zgraggen J; Messmer F; Puippe G; Sartoretti T; Alkadhi H; Pfammatter T; Mannil M
    Eur J Radiol Open; 2021; 8():100375. PubMed ID: 34485629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paraneoplastic Diarrhea From Medullary Thyroid Carcinoma Resolved With Yttrium-90 Radioembolization of Liver Metastases.
    Hamidi S; Mahvash A; Hu MI
    JCEM Case Rep; 2024 Aug; 2(8):luae103. PubMed ID: 39076377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeated radioembolization in advanced liver cancer.
    Masthoff M; Schindler P; Harders F; Heindel W; Wilms C; Schmidt HH; Pascher A; Stegger L; Rahbar K; Wildgruber M; Köhler M
    Ann Transl Med; 2020 Sep; 8(17):1055. PubMed ID: 33145274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Toxicity after Transarterial Radioembolization with Yttrium-90 Using Resin Microspheres for Neuroendocrine Tumor Liver Metastases.
    Tomozawa Y; Jahangiri Y; Pathak P; Kolbeck KJ; Schenning RC; Kaufman JA; Farsad K
    J Vasc Interv Radiol; 2018 Jun; 29(6):858-865. PubMed ID: 29724520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apparent diffusion coefficients (ADC) in response assessment of transarterial radioembolization (TARE) for liver metastases of neuroendocrine tumors (NET): a feasibility study.
    Katharina Ingenerf M; Karim H; Fink N; Ilhan H; Ricke J; Treitl KM; Schmid-Tannwald C
    Acta Radiol; 2022 Jul; 63(7):877-888. PubMed ID: 34225464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial Radioembolization Treatment of Pancreatic Cancer Patients with Liver-Dominant Metastatic Disease Using Yttrium-90 Glass Microspheres: A Single-Institution Retrospective Study.
    Kayaleh R; Krzyston H; Rishi A; Naziri J; Frakes J; Choi J; El-Haddad G; Parikh N; Sweeney J; Kis B
    J Vasc Interv Radiol; 2020 Jul; 31(7):1060-1068. PubMed ID: 32534978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Effects of Yttrium-90 Transarterial Radioembolization around Immunotherapy for Hepatic Metastases from Uveal Melanoma: A Preliminary Retrospective Case Series.
    Zheng J; Irani Z; Lawrence D; Flaherty K; Arellano RS
    J Vasc Interv Radiol; 2018 Oct; 29(10):1369-1375. PubMed ID: 30174161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis.
    Egger ME; Armstrong E; Martin RC; Scoggins CR; Philips P; Shah M; Konda B; Dillhoff M; Pawlik TM; Cloyd JM
    J Am Coll Surg; 2020 Apr; 230(4):363-370. PubMed ID: 32032719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. For Hepatocellular Carcinoma Treated with Yttrium-90 Microspheres, Dose Volumetrics on Post-Treatment Bremsstrahlung SPECT/CT Predict Clinical Outcomes.
    Taswell CS; Studenski M; Pennix T; Stover B; Georgiou M; Venkat S; Jones P; Zikria J; Thornton L; Yechieli R; Mohan P; Portelance L; Spieler B
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers associated with survival and favourable outcome of radioembolization with yttrium-90 glass microspheres for colon cancer liver metastases: Single centre experience.
    Triviño-Ibáñez EM; Pardo Moreno P; Ciampi Dopazo JJ; Ramos-Font C; Ruiz Villaverde G; González-Flores E; Navarro Vergara PF; Rashki M; Gómez-Río M; Rodríguez-Fernández A
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(4):231-238. PubMed ID: 34454892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Radioembolization in the Management of Liver-Dominant Metastatic Renal Cell Carcinoma: A Single-Center, Retrospective Study.
    Bibok A; Mhaskar R; Jain R; Zhang J; Frakes J; Hoffe S; El-Haddad G; Parikh N; Ahmed A; Fishman MN; Choi J; Kis B
    Cardiovasc Intervent Radiol; 2021 Nov; 44(11):1755-1762. PubMed ID: 34312688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study.
    Kolligs F; Arnold D; Golfieri R; Pech M; Peynircioglu B; Pfammatter T; Ronot M; Sangro B; Schaefer N; Maleux G; Munneke G; Pereira H; Zeka B; de Jong N; Helmberger T;
    JHEP Rep; 2023 Feb; 5(2):100633. PubMed ID: 36593888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial Yttrium-90 Glass Microsphere Radioembolization of Chemotherapy-Refractory Breast Cancer Liver Metastases: Results of a Single Institution Retrospective Study.
    Barakat E; Bibok A; Rishi A; Ahmed A; Frakes JM; Hoffe SE; Armaghani AJ; Soyano AE; Costa RLB; El-Haddad G; Choi J; Kis B
    Adv Radiat Oncol; 2022; 7(1):100838. PubMed ID: 35071835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial Radioembolization of Hepatocellular Carcinoma, Liver-Dominant Hepatic Colorectal Cancer Metastases, and Cholangiocarcinoma Using Yttrium90 Microspheres: Eight-Year Single-Center Real-Life Experience.
    Pellegrinelli J; Chevallier O; Manfredi S; Dygai-Cochet I; Tabouret-Viaud C; Nodari G; Ghiringhelli F; Riedinger JM; Popoff R; Vrigneaud JM; Cochet A; Aho S; Latournerie M; Loffroy R
    Diagnostics (Basel); 2021 Jan; 11(1):. PubMed ID: 33466706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of results after 112 radioembolizations with
    Casáns-Tormo I; Guijarro-Rosaleny J; Lluch-García P; Rodríguez-Parra H; Roselló-Keränen S; Asensio-Valero L
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(4):255-264. PubMed ID: 37269983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computed tomographic perfusion imaging for the prediction of response and survival to transarterial radioembolization of liver metastases.
    Morsbach F; Pfammatter T; Reiner CS; Fischer MA; Sah BR; Winklhofer S; Klotz E; Frauenfelder T; Knuth A; Seifert B; Schaefer N; Alkadhi H
    Invest Radiol; 2013 Nov; 48(11):787-94. PubMed ID: 23748229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of Yttrium-90 radioembolization in the treatment of neuroendocrine liver metastases. Long-term monitoring and impact on survival.
    Tudela-Lerma M; Orcajo-Rincón J; Ramón-Botella E; Álvarez-Luque A; González-Leyte M; Rotger-Regi A; Velasco-Sánchez E; Colón-Rodríguez A
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021; 40(2):82-90. PubMed ID: 33239249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transarterial radioembolization with yttrium-90 of unresectable primary hepatic malignancy in children.
    Aguado A; Ristagno R; Towbin AJ; Gupta A; Haberle S; Qi Z; Patel MN; Kukreja KU; Tiao GM; Geller JI
    Pediatr Blood Cancer; 2019 Jul; 66(7):e27510. PubMed ID: 30406959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative volumetric functional MR imaging: an imaging biomarker of early treatment response in hypo-vascular liver metastasis patients after yttrium-90 transarterial radioembolization.
    Zhu X; Sobhani F; Xu C; Pan L; Ghasebeh MA; Kamel IR
    Abdom Radiol (NY); 2016 Aug; 41(8):1495-504. PubMed ID: 26960726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.